Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Rubius Therapeutics is biologically engineering red blood cells to provide a new class of off-the-shelf cellular therapies for cancer and autoimmune diseases. Three of its product candidates, RTX-240, RTX-224 and RTX-321 are progressing through phase 1 clinical trials for advanced cancers.
With a lead candidate harnessing antibody-driven cytotoxic mechanisms to drive tumor cell death, Byondis is developing a pipeline of candidates targeting oncology by combining its unrivaled expertise in linker-drug technology, antibody–drug conjugation, targeted cytotoxic therapy and the development of monoclonal antibodies.
Ellipses Pharma has implemented a disruptive approach to cancer drug development that greatly accelerates the delivery of novel solutions for patients. With seven lead products and a growing pipeline of assets, the company is planning to have a first drug ready for out-licensing in 2024.
ExosomeDx, together with its parent company Bio-Techne, combines expertise in exosome technologies with experience in the non-invasive liquid biopsy market to create solutions for companion diagnostic development and biopharmaceutical services.
A highly sensitive, multi-analyte blood test from Helio Health points to earlier detection of hepatocellular carcinoma and shows promise for a future of widely accessible cancer detection.
With its unique multi-targeted T cell-based immunotherapies that simultaneously attack tumors and trigger a broad spectrum antitumor immune response, Marker has generated promising clinical data in more than 150 patients in both hematological malignancies and solid tumors.
Chordia Therapeutics is developing small-molecule anticancer drugs with novel mechanisms of action and a focus on inducing stress overload in RNA deregulation.
Using a suite of proprietary components, Vincerx Pharma has created a tuneable, modular platform to develop a new generation of novel conjugated cancer therapies with improved safety and efficacy.
TargImmune is developing first-in-class targeted apoptotic immune modulators (TAIMs) based on the Ta:RNA technology platform which mimics viral infection by selectively delivering viral-like double-stranded RNA to tumor cells and harnessing the body’s antiviral defence mechanism against cancer.
PanTher Therapeutics is targeting solid tumors through direct, localized, and sustained delivery of therapeutic agents. The company’s lead program is in a phase 1 trial, and the company is seeking partners to further develop its platform.
Aiding the immune response in the fight against cancer, TILT Biotherapeutics is developing armed oncolytic viruses that replicate in cancer cells making them more discoverable by T cells and other immunotherapies.
With a focus on detecting, intercepting, treating, and ultimately curing cancer, Janssen Oncology is advancing science and solutions in hematologic malignancies and solid tumors through an innovative strategic partnering approach.
Infectious disease diagnostics were prominent among mergers and acquisitions in the molecular diagnostics field, while financing flowed to companies developing liquid biopsy technology.
Indivumed is committed to the advancement of precision oncology solutions by harnessing deep multi-omics data from its highly standardized proprietary tissue bank, bioinformatics and artificial intelligence-integrated advanced data analytics.
RNA-based complementary and companion diagnostics could identify more patients able to receive clinical benefit from cancer therapeutics and increase response rates. Employing its expertise in RNA gene signatures, GeneCentric is developing these novel diagnostics through strategic partnerships with biopharma and diagnostics companies.
Using an aptamer-based approach, SomaLogic can identify up to 7,000 proteins at high levels of specificity, providing real-time precision proteomics for use in the lab and the clinic.
Foresight Diagnostics has developed a platform that detects circulating tumor DNA at levels below one part-per-million, allowing accurate identification of minimal residual disease well below current levels of detection. With testing available for B cell lymphomas and solid tumors, Foresight offers partnering opportunities ranging from investigational through prospective clinical studies and companion diagnostic development.
TransCode Therapeutics has developed an iron oxide nanoparticle–based therapeutic RNA delivery system that maximizes targeted tumor uptake while minimizing clearance. With a lead candidate in metastasis and several preclinical programs targeting other cancers, the company is rapidly expanding its portfolio.
